--- title: "Is PACS Group (PACS) Still Cheap Following Its Q2 Beat And Raised 2026 Outlook?" type: "News" locale: "en" url: "https://longbridge.com/en/news/295480817.md" description: "PACS Group (PACS) stock has gained investor attention following a Q2 earnings beat and raised 2026 guidance, driving an 8.88% price increase over seven days. While bulls highlight strong figures and undervaluation relative to a $59.75 fair value estimate, bears caution that gains may already be priced in. The company is also progressing with Eduro Healthcare facility acquisitions, though risks include integration challenges and reimbursement policy changes." datetime: "2026-08-11T03:46:41.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295480817.md) - [en](https://longbridge.com/en/news/295480817.md) - [zh-HK](https://longbridge.com/zh-HK/news/295480817.md) generator: "portal-rs" --- # Is PACS Group (PACS) Still Cheap Following Its Q2 Beat And Raised 2026 Outlook? ## Why PACS Group Stock Is Back on Investors’ Radar PACS Group (PACS) has attracted fresh attention after reporting its second quarter 2026 results and raising full year revenue and adjusted EBITDA guidance, alongside progress on the Eduro Healthcare facility acquisitions. See our latest analysis for PACS Group. The earnings beat and upgraded 2026 guidance have coincided with stronger trading in PACS Group, with a 7 day share price return of 8.88% and year to date share price return of 22.63%. Over the past year the stock’s total shareholder return of 326.5% points to strong longer term momentum around the story. If PACS Group’s recent move has you thinking about what else is gaining attention in healthcare, this could be a good moment to scan 43 healthcare AI stocks Bulls point to PACS Group’s strong Q2 figures and raised 2026 outlook. Bears focus on how much of that is already in the share price after the recent run. Do the valuation numbers still support the optimistic view? ## Most Popular Narrative: 18.9% Undervalued The most followed narrative sees PACS Group trading below its fair value of $59.75 compared with the last close at $48.45, which puts the focus squarely on what is baked into those long term assumptions. > *Systematic improvement of newly acquired and turnaround facilities from low single digit margins toward the high single digit and low double digit margin profile of mature sites should unlock embedded profitability, lifting consolidated net margins and EBITDA over time.* *Read the complete narrative.* Want to see what powers that $59.75 fair value for PACS Group? The narrative leans heavily on rising revenue, fatter margins, and a richer future earnings multiple. The exact mix of those assumptions might surprise you. **Result: Fair Value of $59.75 (UNDERVALUED)** Have a read of the narrative in full and understand what's behind the forecasts. However, PACS Group’s story could change if the integration of the newly acquired facilities drags on, or if reimbursement policies in key states turn less favorable. Find out about the key risks to this PACS Group narrative. ## Next Steps With sentiment around PACS Group clearly mixed, now is a useful time to look through the numbers yourself and decide where you stand. To see both sides of the story in one place, review the 4 key rewards and 1 important warning sign. ## Looking for more PACS Group style investment ideas? If PACS Group has sharpened your focus on finding stronger opportunities, do not stop here. Use the Simply Wall St Screener now to uncover more targeted ideas. - Spot potential value opportunities early by scanning the 51 high quality undervalued stocks that currently fit your quality and valuation filters. - Strengthen your downside protection by reviewing the 83 resilient stocks with low risk scores that score well on resilience and risk checks. - Get ahead of the crowd by searching the screener containing 21 high quality undiscovered gems that combine solid fundamentals with limited current attention. *This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.* ### **New:** Manage All Your Stock Portfolios in One Place We've created the **ultimate portfolio companion** for stock investors, **and it's free.** • Connect an unlimited number of Portfolios and see your total in one currency • Be alerted to new Warning Signs or Risks via email or mobile • Track the Fair Value of your stocks Try a Demo Portfolio for Free ### Related Stocks - [PACS.US](https://longbridge.com/en/quote/PACS.US.md) ## Related News & Research - [Is Partial Claim Dismissal Altering The Investment Case For PACS Group (PACS)?](https://longbridge.com/en/news/298702503.md) - [PACS Group Co-Founder, CEO and Chairman Murray Jason Hulse sells USD 2.22 million in common shares](https://longbridge.com/en/news/298507687.md) - [PACS Group closes on 11 additional Eduro Healthcare facilities acquisition](https://longbridge.com/en/news/297948546.md) - [PACS Group CEO and Chairman Jason Hulse sells USD 2.91 million common shares](https://longbridge.com/en/news/297970499.md) - [Stevanato Group to Present at Morgan Stanley Global Healthcare Conference](https://longbridge.com/en/news/298359621.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**